Lilly is Dicerna's second RNAi partner in a week
Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna has made within a week.
The partners will use Dicerna's GalXC technology to develop next-generation oligonucleotide therapies for more than ten targets in the three therapeutic areas. Dicerna will receive $100 million up front and Lilly will invest $100 million in the RNAi company. Dicerna is eligible for up to about $350 million per target in development and commercialization milestones, plus mid-single to low-double digit royalties...